Biotech startup emerges from stealth with $65M to tackle lung cancer


Ribon Therapeutics hopes its lead program can restrain an enzyme that is activated by environmental stresses like cigarette smoking and allows cancerous cells to dodge the body's immune system.

Previous Hospitals provide charges online, but it's not as useful as you might think
Next Denver housing market suffers drastic swing in 2018